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mIt is proposed that the initial step in the
process leading directly to coronary thrombosis is
the development, with advancing age,
of what can be termed
a “vulnerable atherosclerotic plaque.”
—Muller et al. (1)
Coronary atherothrombosis is the leading single
cause of death in the United States and Europe.
Since the original description of angina by He-
berden in 1772 (2), great strides have been made
toward elucidating the processes that result in the
development and progression of atherosclerosis.
See page 894
The lesion substrate prone to thrombosis was
termed “vulnerable plaque,” initially defined func-
tionally as “the susceptibility of a plaque to rupture”
(1). As described from human autopsy studies,
atherosclerosis progresses from a benign phenotype
(most typically pathological intimal thickening) to
the more ominous fibroatheroma, characterized by
a large necrotic core containing free cholesterol
crystals and cholesterol esters (3). As the plaque
becomes more inflamed and metabolically active,
the fibrous cap becomes infiltrated with macro-
phages and T-lymphocytes, smooth muscle cells
become depleted, the ratio of type I to type III
collagen increases, and the fibrous cap thins, be-
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TCFA). Less commonly, the vulnerable plaque
henotype may be represented by an erosion-prone
roteoglycan-rich lesion or a calcific nodule. Re-
ardless, the precipitating clinical event is arterial
hrombosis, which, depending on the underlying
laque severity and the efficacy of the body’s endog-
nous fibrinolytic system, results in a clinical spec-
rum of presentations ranging from sudden cardiac
eath due to coronary occlusion to an asymptomatic
vent with plaque progression.
A more clinically relevant definition of a vulner-
ble plaque is a lesion that places a patient at risk for
uture major adverse cardiac events (MACE), in-
luding death, myocardial infarction, or progressive
ngina. The identification of such plaques before
hey become symptomatic would afford prognostic
tratification and facilitate primary prevention (e.g.,
spirin, statins, and risk factor modification), per-
aps one day including prophylactic focal or re-
ional coronary therapy. Ironically, an advanced
nderstanding of plaque vulnerability has been hin-
ered for more than 2 decades by the very tool that
ntil recently was considered the gold standard for
he diagnosis of ischemic heart disease, namely,
oronary arteriography. Intravascular ultrasound
IVUS) has exposed the major limitations of an-
iography, first and foremost the fact that the
ngiographic representation of the coronary lumen
bscures the true plaque burden, leading to an
nderestimation of plaque severity (4). Because of
his, serial retrospective angiographic studies sug-
ested that most lesions that caused future myocar-
ial infarctions were mild in severity (5), an obser-
ation at odds with earlier prospective studies
howing that more severe angiographic stenoses
ere more likely to occlude (6), and pathological
tudies demonstrating that plaques that caused
yocardial infarction and sudden death tended toave a large plaque burden (3).
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903In order to identify lesion and vessel characteris-
tics that place patients at risk for future MACE,
more than 2 dozen invasive and noninvasive tech-
nologies have been developed to characterize the
compositional, physical, cellular, and biochemical
signatures specific to pathological vulnerable
plaque. Given their proximity to the plaque, intra-
vascular catheters have the inherent advantage of a
high signal-to-noise ratio, and 3 such imaging tools
have emerged for clinical use: radiofrequency IVUS,
optical coherence tomography, and near-infrared
spectroscopy. Each imaging technique produces a
graphical representation of the vessel wall with
purported “vulnerable” characteristics, the accuracy
of each having been validated to a greater or lesser
degree against human histology. However, prior to
clinical use of these tools, the image patterns that
each generate must be validated to predict future
MACE with reasonable sensitivity and specificity.
In this regard, the PROSPECT (Providing Re-
gional Observations to Study Predictors of Events
in the Coronary Tree) study (7) was a multicenter,
multimodality imaging study to prospectively char-
acterize the coronary tree with 3-vessel intravascular
imaging, and map subsequent events to untreated
(nonculprit) lesions versus previously treated culprit
lesions. Performed in 697 patients at 37 sites in the
United States and Europe, the PROSPECT study
prospectively characterized 3,160 nonculprit le-
sions, demonstrating by multivariable analysis that
the 3 independent baseline predictors of future
nonculprit-lesion–related MACE during a median
follow-up of 3.4 years were a large plaque burden, a
small lumen area, and a TCFA as classified by
radiofrequency IVUS (VH-IVUS). Of note, the
lesions fated to cause future MACE were mild at
baseline by angiography (mean diameter stenosis of
32  21%), but not by IVUS (mean plaque burden
f 67  10%), and progressed substantially to the
ime of the follow-up MACE (to an angiographic
ean diameter stenosis of 65  16%).
The ability to detect vulnerable plaque has sig-
ificant implications for future research and clinical
are, and the results from any single study, no
atter how robust, should be replicated before
eing accepted. In this regard, the findings from the
IVA (VH-IVUS in Vulnerable Atherosclerosis)
tudy are noteworthy. As reported by Calvert et al.
8) in this issue of iJACC, 3-vessel VH-IVUS was
erformed in the coronary arteries of 170 patients
1,096 lesions) with stable or unstable ischemic
eart disease. At a median follow-up of 1.7 years,
he strongest univariate correlates of future noncul-rit-lesion–related MACE were large plaque bur-
en, small lumen area, remodeling index, and a
CFA as classified by VH-IVUS. Although there
re several important differences between PROSPECT
nd VIVA (multicenter vs. single center, 697 vs.
70 patients, inclusion of stable angina patients in
IVA, slightly different definitions of TCFA and
ACE, different durations of follow-up, among others),
he consistency of the findings with PROSPECT
alidate not only the clinical utility of VH-IVUS to
etect vulnerable plaques, but also the concept
tself, as a pathological and clinical entity, as linked
y the imaging tool.
For certain, more information is required from
IVA, and several limitations deserve mention.
urprisingly, neither the clinical characteristics,
ngiographic findings, nor the pharmacological
reatments of the patient cohort are reported in the
aper. Greater details about the patient-level plaque
haracterization and adjudication processes are nec-
ssary. The number of nonculprit events is too few
o support multivariable analysis without model
verfitting, and although the frequency of death
nd myocardial infarction were comparable to
ROSPECT, detailed data on the rates of rehos-
italization and recurrent angina are not provided.
oreover, both VIVA and PROSPECT leave
everal important questions unaddressed:
. What is the temporal stability of vulnerable
plaque (9)? Neither study incorporated routine
angiographic or intravascular imaging follow-up
so as to not disrupt the natural history experiment.
. How should VH-IVUS TCFAs be treated (and
by corollary, should we screen for their pres-
ence)? Randomized trials to address these issues
will be difficult and costly.
. Can the findings from VH-IVUS be used to
guide drug development? In this regard, the
observation that the lipoprotein-associated
phospholipase A2 (Lp-PLA2) inhibitor darap-
ladib halted necrotic core expansion in patients
with acute coronary syndromes and coronary
artery disease was 1 of the motivating forces for
the large-scale randomized STABILITY (Sta-
bilization of Atherosclerotic Plaque by Initia-
tion of Darapladib Therapy) trial (10).
. Can the accuracy of core laboratory–based VH-
IVUS lesion characterization be replicated at
clinical sites? Automated edge-detection and
pattern recognition software is required to re-
duce interobserver variability.
. Is the accuracy of other imaging tools to detect
vulnerable plaque as good as or better than
6o
s
v
d
r
f
t
d
C
s
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 8 , 2 0 1 1
A U G U S T 2 0 1 1 : 9 0 2 – 4
Stone et al.
Editorial Comment
904VH-IVUS? Optical coherence tomography and
near-infrared spectroscopy each require their
own natural history study for validation, ideally
compared with each other and VH-IVUS.
. And finally, what is the utility of noninvasive
atherosclerosis imaging with multidetector
computed tomography and magnetic resonance
imaging? Such tools should be preferable for
primary screening of high-risk, asymptomatic
patients, reserving catheter-based plaque assess-
ment for confirmation, and for secondary
screening after symptomatic patient presenta-5. Ambrose JA, Tannenbaum MA,
Alexopoulos D, et al. Angiographic
erosclerosis) study.
Img 2011;4:894–90In summary, although a complete understanding
f the etiology and mechanisms of atherothrombo-
is remains an elusive goal, VH-IVUS has been
alidated as a tool capable of providing incremental
iscrimination to identify patients and lesions at
isk for future MACE. It is our hope that this
undamental knowledge will provide the foundation
o develop new therapies to prevent acute myocar-
ial infarction and sudden cardiac death.
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